are used to treat acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated urinary tract infections.
have been shown to adversely affect tendons, nerves, the heart and the central nervous system in patients of all ages.
Patients taking fluoroquinolones
must also be vigilant and let their provider know immediately if they begin suffering from any new pain in their joints, tendons, or muscles.
Our study will be first of its kind as no other prospective cohort study on the use of fluoroquinolones
and its relation to development of psychosis has yet been carried out despite of the large number of cases.
vary in the spectrum of antimicrobial activity.
A respiratory fluoroquinolone
such as levofloxacin might be considered for treatment of nonmeningeal multidrug-resistant pneumococcal infection.
In addition to detecting increasing fluoroquinolone
resistance in MDR isolates, we have also detected fluoroquinolone
resistance in non-MDR, polydrug-resistant M.
Empirical treatment with a fluoroquinolone
delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas.
Overall, patients who had used fluoroquinolone
within 12 months of diagnosis were almost five times as likely to have a fluoroquinolone
-resistant strain of TB than those who had not used the antibiotics.
The authors identified 11 studies that compared a fluoroquinolone
with a beta-lactam for ABRS.
antibiotics are considered highly effective to treat various forms of bacterial infections, although they have complicated safety profiles.
Ciprofloxacin, a second-generation fluoroquinolone
, is an effective single-dose oral chemoprophylaxis agent.
Doctors use the fluoroquinolone
class of antibiotics to treat food poisoning caused by Campylobacter.
1) Data from a CDC surveillance system show steady and widespread increases in fluoroquinolone
resistance since the late 1990s; between 2001 and the first half of 2006, the proportion of gonorrhea infections that were resistant to these drugs rose from less than 1% to 7% among heterosexual men.
Audience members questioned if the findings were representative of family care in the United States, particularly in light of the high fluoroquinolone
use that was reported.